UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): December 31, 2016
ANTHERA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-34637
|
|
20-1852016
|
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
25801 Industrial Boulevard, Suite B, Hayward,
California |
|
94545
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (510) 856-5600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On December 31, 2016 BVF Partners, LP (“BVF”) gave written notice to Anthera Pharmaceuticals, Inc. (the “Company”) that it was abandoning 100% of its rights to acquire Series X-1 Convertible Preferred Stock of the Company pursuant to the terms of the subscription agreement by and among the Company and purchasers affiliated with BVF and Rock Springs Capital Master Fund LP, dated September 6, 2016.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: January 6, 2016
|
Anthera Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ May Liu
|
|
|
|
May Liu
|
|
|
|
Senior Vice President, Finance and Administration
|